Bypassing agent regimens and costs for prophylaxis in patients with inhibitors

被引：0
|
作者：
Gringeri, A. [1 ,2 ]
机构：
[1] IRCCS Maggiore Policlin, Dept Med & Med Special, Angelo Bianchi Bonomi Haemophilia & Thrombosis Ct, Regina Elena Hosp Fdn, I-20122 Milan, Italy
[2] Univ Milan, Milan, Italy
来源：
HAEMOPHILIA | 2009年 / 15卷 / 06期
关键词：
HEMOPHILIA-A;
D O I：
10.1111/j.1365-2516.2009.02068.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1336 / 1337
页数：2
相关论文
共 50 条
  • [41] Bisphosphonate prophylaxis in Lymphoma patients treated with steroid containing regimens
    Chandrashekar, Rashmi
    Martinez-Calle, Nicolas
    Al Shalabi, Mufid
    McMillan, Andrew
    Richardson, Faith
    Adlington, Joanne
    Ellison, Louise
    Fox, Christopher P.
    Bishton, Mark
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 111 - 111
  • [42] Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors
    Berntorp, E.
    HAEMOPHILIA, 2009, 15 (01) : 3 - 10
  • [43] Mechanisms and monitoring of bypassing agent therapy
    Hoffman, M.
    Dargaud, Y.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (08) : 1478 - 1485
  • [44] Healthcare costs among patients with hemophilia A treated with factor replacement or bypassing agents
    Swindle, Jason P.
    Xu, Yaping
    Mu, Yunming
    Solari, Paul G.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (08) : 1433 - 1440
  • [45] Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors
    Bykov, Katsiaryna
    Bohn, Rhonda L.
    Ewenstein, Bruce M.
    Seeger, John D.
    Avorn, Jerry
    Bateman, Brian T.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (12) : 2267 - 2273
  • [46] Global haemostatic assays in monitoring the effect of bypassing agent therapy in haemophilia A patients with inhibitors-an in-vivo prospective crossover study
    Tran, H. T. T.
    Bjornsen, S.
    Ueland, T.
    Pripp, A. H.
    Tjonnfjord, G.
    Holme, P. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 923 - 923
  • [47] REDUCTION OF COSTS ASSOCIATED WITH THE USE OF EMICIZUMAB IN PROPHYLAXIS IN PEDIATRIC PATIENTS DIAGNOSED WITH SEVERE HEMOPHILIA A AND INHIBITORS IN EL SALVADOR
    Estrada, A.
    Galdamez, C.
    Castillo, D.
    Ventura, B.
    VALUE IN HEALTH, 2024, 27 (06) : S116 - S116
  • [48] Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study
    Mancuso, Maria Elisa
    Callaghan, Michael U.
    Kruse-Jarres, Rebecca
    Kempton, Christine L.
    Xu, Jin
    Catalani, Olivier
    Asikanius, Elina
    Levy, Gallia G.
    Shima, Midori
    Young, Guy
    Oldenburg, Johannes
    BLOOD, 2017, 130
  • [49] Emicizumab Prophylaxis in Adolescent/Adult Patients with Haemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study
    Mancuso, M. E.
    Oldenburg, J.
    Callaghan, M.
    Kruse-Jarres, R.
    Kempton, C.
    Xu, J.
    Catalani, O.
    Asikanius, E.
    Levy, G. G.
    Shima, M.
    Young, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 127 - 127
  • [50] Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    HAEMOPHILIA, 2020, 26 (01) : 41 - 46
12345